-
1
IL-5 is crucial for eosinophil biology, influencing their differentiation, survival, and recruitment to inflamed tissues.
-
2
Four biologics targeting the IL-5/IL-5Rα pathway are mepolizumab, reslizumab, benralizumab, and depemokimab, each with distinct mechanisms.
-
3
Mepolizumab effectively reduces exacerbations and eosinophil levels in severe eosinophilic asthma, chronic rhinosinusitis, and other conditions.
-
4
Benralizumab induces rapid eosinophil depletion and has shown corticosteroid-sparing effects in severe eosinophilic asthma and EGPA.
-
5
Safety profiles of IL-5 inhibitors are generally reassuring, with most adverse events being mild to moderate in nature.
